ATEA PHARMACEUTICALS INC (AVIR) Fundamental Analysis & Valuation

NASDAQ:AVIR • US04683R1068

Current stock price

5.58 USD
+0.22 (+4.1%)
At close:
5.51 USD
-0.07 (-1.25%)
Pre-Market:

This AVIR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. AVIR Profitability Analysis

1.1 Basic Checks

  • In the past year AVIR has reported negative net income.
  • In the past year AVIR has reported a negative cash flow from operations.
  • AVIR had negative earnings in 4 of the past 5 years.
  • AVIR had a negative operating cash flow in each of the past 5 years.
AVIR Yearly Net Income VS EBIT VS OCF VS FCFAVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -50.23%, AVIR is doing worse than 64.40% of the companies in the same industry.
  • The Return On Equity of AVIR (-57.49%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -50.23%
ROE -57.49%
ROIC N/A
ROA(3y)-25.47%
ROA(5y)-12.4%
ROE(3y)-26.96%
ROE(5y)-13.16%
ROIC(3y)N/A
ROIC(5y)N/A
AVIR Yearly ROA, ROE, ROICAVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AVIR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVIR Yearly Profit, Operating, Gross MarginsAVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. AVIR Health Analysis

2.1 Basic Checks

  • AVIR has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, AVIR has less shares outstanding
  • AVIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AVIR Yearly Shares OutstandingAVIR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AVIR Yearly Total Debt VS Total AssetsAVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 3.54 indicates that AVIR is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.54, AVIR is doing good in the industry, outperforming 67.02% of the companies in the same industry.
  • There is no outstanding debt for AVIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.54
ROIC/WACCN/A
WACCN/A
AVIR Yearly LT Debt VS Equity VS FCFAVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 7.82 indicates that AVIR has no problem at all paying its short term obligations.
  • The Current ratio of AVIR (7.82) is better than 76.44% of its industry peers.
  • A Quick Ratio of 7.82 indicates that AVIR has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 7.82, AVIR is doing good in the industry, outperforming 76.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.82
Quick Ratio 7.82
AVIR Yearly Current Assets VS Current LiabilitesAVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. AVIR Growth Analysis

3.1 Past

  • AVIR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.00%.
EPS 1Y (TTM)3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 3.75% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.72%
EPS Next 2Y6.17%
EPS Next 3Y3.75%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVIR Yearly Revenue VS EstimatesAVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2027 2028 100M 200M 300M
AVIR Yearly EPS VS EstimatesAVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. AVIR Valuation Analysis

4.1 Price/Earnings Ratio

  • AVIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AVIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVIR Price Earnings VS Forward Price EarningsAVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVIR Per share dataAVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.17%
EPS Next 3Y3.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVIR Dividend Analysis

5.1 Amount

  • AVIR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVIR Fundamentals: All Metrics, Ratios and Statistics

ATEA PHARMACEUTICALS INC

NASDAQ:AVIR (4/28/2026, 8:14:02 PM)

Premarket: 5.51 -0.07 (-1.25%)

5.58

+0.22 (+4.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength65.22
Industry Growth16.77
Earnings (Last)01-08
Earnings (Next)05-13
Inst Owners72.36%
Inst Owner Change-0.05%
Ins Owners6.08%
Ins Owner Change17.12%
Market Cap444.56M
Revenue(TTM)N/A
Net Income(TTM)-158.35M
Analysts82.22
Price Target8.16 (46.24%)
Short Float %11.15%
Short Ratio15.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.77%
Min EPS beat(2)-18.09%
Max EPS beat(2)-5.44%
EPS beat(4)1
Avg EPS beat(4)-5.78%
Min EPS beat(4)-18.09%
Max EPS beat(4)4.35%
EPS beat(8)3
Avg EPS beat(8)1.86%
EPS beat(12)7
Avg EPS beat(12)6.72%
EPS beat(16)11
Avg EPS beat(16)13.26%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)33.33%
PT rev (3m)33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.32%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.61
P/tB 1.61
EV/EBITDA N/A
EPS(TTM)-1.94
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-1.7
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS0
BVpS3.46
TBVpS3.46
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -50.23%
ROE -57.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.47%
ROA(5y)-12.4%
ROE(3y)-26.96%
ROE(5y)-13.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.82
Quick Ratio 7.82
Altman-Z 3.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.5%
EPS Next Y12.72%
EPS Next 2Y6.17%
EPS Next 3Y3.75%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.88%
EBIT Next 3Y13.01%
EBIT Next 5Y17%
FCF growth 1Y-58.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.67%
OCF growth 3YN/A
OCF growth 5YN/A

ATEA PHARMACEUTICALS INC / AVIR Fundamental Analysis FAQ

What is the fundamental rating for AVIR stock?

ChartMill assigns a fundamental rating of 3 / 10 to AVIR.


What is the valuation status of ATEA PHARMACEUTICALS INC (AVIR) stock?

ChartMill assigns a valuation rating of 0 / 10 to ATEA PHARMACEUTICALS INC (AVIR). This can be considered as Overvalued.


What is the profitability of AVIR stock?

ATEA PHARMACEUTICALS INC (AVIR) has a profitability rating of 0 / 10.